Navigation Links
Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
Date:8/6/2009

products are out-licensed to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed four products with global combined sales in excess of $2.6 billion in 2008.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com.

About Curis, Inc.

Curis is a drug development company that is committed to leveraging its innovative signalling pathway drug technologies to seek to create new medicines for cancer indications. In expanding its drug development efforts in the field of cancer through its targeted cancer drug development platform, Curis is building upon its previous experiences in targeting signalling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at http://www.curis.com.

Curis Cautionary Statement: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation the Company's statements regarding: the expected timing and amount of payments to be received by Curis under the license agreement with Debiopharm and the expected benefits of the agreement; Debiopharm's plans to seek approval for the commencement of a phase I clinical trial in Fall 2009; the estimated period in which Curis will have cash to meet its operating requirements and its assumptions about factors that may positively affect such period; expectations regarding the potential benefits of CUDC- 305; its ability to further progres
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
2. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
3. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
4. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
5. Japanese Cancer Association and Debiopharm Honour Japanese Research
6. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
7. Debiopharm and EPFL Establish an Oncology Chair
8. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
9. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
10. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
11. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... information — Global biopharmaceutical company UCB, Inc. and professional ... of a new Pledge campaign for people with epilepsy ... empowers the millions of Americans living with epilepsy ... to demand more: greater understanding of the condition, better ... seizure control.  More information is available at www.ourtimeourpledge.com ...
(Date:6/18/2013)... June 18, 2013 The "Bioinformatics Market By ... Knowledge Management Tools & Data Analysis Services) & Application (Genomics, ... the Major Market Drivers, Restraints, and Opportunities in ... Asia-Pacific and Rest of World. ... 22 Figures 364 ...
(Date:6/18/2013)... Canada (PRWEB) June 18, 2013 ... oversight of pharmaceutical advertising and promotion, and review ... Viewers will learn how to apply these principles ... examples:, ,     The fundamentals on FDA ... and promotional labeling ,     Assessing traditional and ...
(Date:6/18/2013)... 2013   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... on discovering breakthrough treatments for human disease, announced ... the company as its vice president of marketing, ... commercial experience to Lexicon, including both pre-launch planning ... areas. Mr. Northcott has held commercial ...
Breaking Biology Technology:Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 2Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 4Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 5Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 6Bioinformatics Market Worth $7.5 Billion by 2017 2Bioinformatics Market Worth $7.5 Billion by 2017 3Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 3
... N.J. and WORCESTER, Mass., April 25, 2012  Quest Diagnostics ... of diagnostic testing, information and services, today announced a ... unit, a leader in neurology diagnostics, for amyotrophic lateral ... It is the first clinically available testing ...
...  A well-respected, independent, third-party laboratory has tested for Tuberculosis ... BNP (BioNanoPore) test kits and achieved the detection ... Standard culture times for conventional technologies take a minimum ... In concurrent tests for TB at the same facility, ...
... 2012 AMRI (NASDAQ: AMRI ) announced ... functions. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) ... teams are being combined into one functional sales organization, ... promoted to Vice President, Business Development, North America. This ...
Cached Biology Technology:Quest Diagnostics Announces C9orf72 Genetic Test for ALS (Lou Gehrig's Disease) 2Quest Diagnostics Announces C9orf72 Genetic Test for ALS (Lou Gehrig's Disease) 3NanoLogix Provides Testing and Operations Update 2NanoLogix Provides Testing and Operations Update 3AMRI Strengthens Business Development and Marketing Groups 2AMRI Strengthens Business Development and Marketing Groups 3
(Date:6/18/2013)... and 10% of breast and ovarian cancers are familial ... are attributable to inherited mutations from the parents in ... these mutations, PARP inhibitors, which are currently in clinical ... new option for personalised cancer treatment, an alternative to ... fraction of these patients generate resistance to the drug ...
(Date:6/17/2013)... in the U.S. exposed to high levels of air pollution ... a child with autism as women who lived in areas ... School of Public Health (HSPH). It is the first large ... across the U.S. , "Our findings raise concerns since, depending ... our study lived in areas where risk of autism was ...
(Date:6/17/2013)... their food may turn out to be just as important ... of St. Michael,s Hospital. , The study, led by ... association between poor eating habits in kids ages three to ... cholesterol, putting them at risk for cardiovascular disease later in ... Medical Association Journal today. , "We know that ...
Breaking Biology News(10 mins):An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2Exposure to high pollution levels during pregnancy may increase risk of having child with autism 2Poor eating behaviors may put preschoolers at risk for later health problems 2
... toxins that affect human health and ecosystems in smoke ... also suggest that smoldering fires may produce more toxins ... to a minimum during controlled burns. Finding ... understand how they cycle through earth and air. Smoke-related ...
... Pacific Northwest National Laboratory will be home to one ... earlier this week by the White House in conjunction ... the annual meeting of the National Academy of Sciences. ... research on energy, are being established by the DOE,s ...
... a remote-controlled camera on the Tahoe National Forest in ... populations, according to a team of 10 federal, state ... the latest edition of Northwest Science and ... first scientifically verified California wolverine in 86 years. The ...
Cached Biology News:Potentially harmful chemicals found in forest fire smoke 2DOE to establish Energy Frontier Research Center at PNNL 2DOE to establish Energy Frontier Research Center at PNNL 3Origins of wolverine in California genetically verified 2
... Radiolabeled Ligands\n\nReceptor-related research has long been enabled ... ligands selected to keep pace with new ... products and services for receptor research and ... If you do not find exactly what ...
... robotic system and disposable ESI Chip allow ... capabilities of electrospray mass spectrometers for life ... allows users to either speed analysis for ... mapping applications, or long acquisition times for ...
... Pulsed Dynamic Focusing MALDI (PDF-MALDI) source provides ... that do not need online separation. Paired ... LC/MS and Agilents powerful Spectrum Mill software, ... analysis of 2D gel-spot digests. It provides ...
... is an all-in-one rotator/rocker with a ... different mixing motions: rotating, rocking/shaking, ... as a combination of all these ... of the Vibraotme Roto-Shake Genie consists ...
Biology Products: